Accretion Pharmaceuticals Ltd

As of November 17, 2025, Accretion Pharmaceuticals is considered overvalued with a shift in valuation from very expensive to expensive, despite strong returns on capital and equity, as its valuation metrics are significantly lower than peers like Sun Pharma and Divi's Lab.

As of November 14, 2025, Accretion Pharmaceuticals is considered very expensive and overvalued despite strong profitability metrics, with a PE ratio of 11.21 and an EV to EBITDA of 7.59, particularly when compared to its peers like Sun Pharma and Divi's Lab.

As of November 14, 2025, Accretion Pharmaceuticals is considered very expensive and overvalued despite strong financial metrics, with a PE ratio of 11.21 and a recent stock performance that outpaced the Sensex.

As of November 14, 2025, Accretion Pharma is considered very expensive and overvalued with a PE Ratio of 11.21 and an EV to EBITDA of 7.59, despite recent strong stock performance compared to its peers like Sun Pharma and Divi's Lab.

Accretion Pha. has shown significant growth from March 2024 to March 2025, with net sales increasing from 13.35 Cr to 57.38 Cr, and profit after tax rising from 1.49 Cr to 6.79 Cr. Key metrics such as operating profit and earnings per share also improved markedly, indicating strong overall financial performance.

Accretion Pha. reported a profit before tax of Rs 2.00 crore for the year ending March 2024, but faced significant cash flow challenges with negative cash flows from operating and investing activities totaling Rs -16.00 crore, offset by a positive cash flow of Rs 17.00 crore from financing activities, resulting in no net cash inflow or outflow. The company had no cash and cash equivalents at the beginning or end of the period, indicating tight liquidity.